ALK and angioimmunoblastic T-cell lymphoma: Responses were seen across all nodal PTCL subgroup including ALK-negative ALCL (53.8%), ALK-positive ALCL (42.9%), PTCL-NOS (17.9%), and AITL (50%) [156].